From: Biomarkers for determining the prognosis in chronic myelogenous leukemia
Name | Year approved | Indications in CML |
---|---|---|
Imatinib | 2001 | CP, AP, or BC after failure of interferon therapy |
2003 | Newly diagnosed CP | |
Dasatinib | 2006 | CP, AP, or BC after resistance to or intolerance of imatinib |
2010 | Newly diagnosed CP | |
Nilotinib | 2007 | CP or AP after resistance to or intolerance of imatinib |
2010 | Newly diagnosed CP | |
Bosutinib | 2012 | CP, AP, or BC after resistance to or intolerance of prior therapy |
Ponatinib | 2012 | CP, AP, or BC after resistance to or intolerance of prior TKI therapy |